Last 33 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -25.82 | — | — | — | 2.97 | — | — | — | — | — | — | — | 3.93 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 18.53 | 2084.59 | 1826.78 | 19.38 | 6.37 | 64.17 | 51.23 | 57.50 | 16.97 | 35.37 | 40.96 | 91.07 | 1.78 | 27.64 | 30.29 | 22.85 | 34.54 | 53.03 | 40.80 | 116.72 | 26.52 |
| — | +3148.4% | +3465.7% | -66.3% | -62.5% | +81.4% | +25.1% | -36.9% | +853.6% | +28.0% | +35.2% | +298.5% | -94.8% | -47.9% | -25.8% | -80.4% | +30.2% | -97.2% | -100.0% | -99.9% | -100.0% | |
| P/B Ratio | 2.11 | 2.69 | 3.35 | 2.11 | 2.35 | 2.58 | 1.66 | 1.53 | 2.78 | 2.55 | 2.26 | 2.95 | 2.29 | 2.44 | 3.00 | 2.91 | 3.77 | 4.69 | 3.40 | 4.75 | 6.55 |
| — | +4.3% | +102.4% | +38.1% | -15.6% | +1.0% | -26.6% | -48.2% | +21.3% | +4.6% | -24.8% | +1.7% | -39.2% | -48.0% | -11.6% | -38.8% | -42.4% | -30.7% | -76.7% | -58.4% | -67.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | 4.28 | — | — | — | — | — | — | 4.66 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | 3.60 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | 2.98 | — | — | — | — | — | — | — | 3.74 | — | — | — | — | — | — | — | 13.68 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 84.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -1044.6% | 55.7% | -481.9% | -385.2% | -311.6% | -330.9% | -439.8% | -347.7% | -675.7% | 213.9% |
| — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +109.6% | +79.5% | +120.8% | +126.0% | -235.2% | +116.8% | -9.6% | -10.8% | +53.9% | -254.7% | +93.8% | +100.0% | +100.0% | +100.0% | |
| Operating Margin | -274.6% | -46033.2% | -25827.1% | -337.8% | -15.3% | -1307.6% | -1419.2% | -1596.9% | -332.7% | -746.4% | -891.1% | -1405.3% | 42.0% | -629.7% | -507.8% | -408.7% | -444.1% | -577.9% | -492.2% | -904.0% | -124.3% |
| — | -3420.4% | -1719.8% | +78.8% | +95.4% | -75.2% | -59.3% | -13.6% | -891.8% | -18.5% | -75.5% | -243.9% | +109.5% | -9.0% | -3.2% | +54.8% | -257.3% | +93.7% | +99.9% | +100.0% | +100.0% | |
| Net Margin | -57.2% | -43780.1% | -25036.3% | -297.2% | 214.1% | -1162.4% | -1208.3% | -1462.8% | -300.5% | -677.5% | -773.5% | -1331.6% | 45.2% | -558.9% | -411.5% | -398.5% | -191.4% | -693.6% | -432.1% | -820.8% | -126.7% |
| — | -3666.4% | -1972.1% | +79.7% | +171.2% | -71.6% | -56.2% | -9.9% | -765.4% | -21.2% | -88.0% | -234.2% | +123.6% | +19.4% | +4.8% | +51.5% | -51.1% | +81.2% | +100.0% | +100.0% | +100.0% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.1% | -13.3% | -11.0% | -7.9% | 22.2% | -11.2% | -9.4% | -11.8% | -11.9% | -11.8% | -10.3% | -10.4% | 16.2% | -12.1% | -10.5% | -12.9% | -5.3% | -14.5% | -8.8% | -8.4% | -7.7% |
| — | -18.8% | -16.6% | +33.3% | +287.0% | +4.7% | +8.5% | -13.0% | -173.0% | +2.7% | +2.1% | +19.3% | +406.3% | +16.5% | -19.1% | -54.4% | +31.2% | -260.8% | +43.8% | +86.1% | +82.0% | |
| ROA | -6.2% | -10.1% | -8.6% | -6.4% | 17.5% | -8.3% | -7.2% | -8.5% | -7.9% | -7.9% | -6.9% | -7.0% | 10.4% | -7.3% | -6.2% | -7.2% | -2.8% | -7.9% | -5.0% | -4.7% | -4.9% |
| — | -21.3% | -19.6% | +25.1% | +320.3% | -5.0% | -3.0% | -21.5% | -176.5% | -9.4% | -12.7% | +3.0% | +464.5% | +8.2% | -23.0% | -52.6% | +42.1% | -188.5% | +47.9% | +86.6% | +81.2% | |
| ROIC | -31.1% | -10.2% | -8.5% | -6.8% | -1.3% | -10.8% | -10.8% | -13.1% | -11.2% | -11.0% | -10.3% | -10.3% | 13.3% | -10.5% | -10.6% | -10.8% | -9.4% | -9.5% | -8.8% | -10.4% | -11.9% |
| — | +5.1% | +20.7% | +48.1% | +88.8% | +2.4% | -4.1% | -26.8% | -184.6% | -4.8% | +2.1% | +4.8% | +240.5% | -11.0% | -19.9% | -4.1% | +20.5% | +21.4% | +6.2% | +77.4% | +44.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.24 | 0.26 | 0.23 | 0.22 | 0.24 | 0.16 | 0.15 | 0.14 | 0.22 | 0.20 | 0.19 | 0.18 | 0.18 | 0.22 | 0.22 | 0.23 | 0.24 | 0.24 | 0.22 | 0.18 | 0.18 |
| — | +63.3% | +56.7% | +53.0% | +7.8% | -23.5% | -23.6% | -23.5% | +25.1% | -7.6% | -10.4% | -20.6% | -27.9% | -9.5% | -2.7% | +28.0% | +36.7% | +43.7% | -14.6% | -44.0% | -59.3% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | 1.25 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 13.09 | 13.00 | 14.57 | 16.99 | 13.09 | 6.02 | 6.75 | 8.81 | 4.82 | 5.69 | 5.81 | 5.99 | 5.89 | 4.72 | 5.22 | 4.92 | 4.89 | 4.64 | 5.56 | 5.66 | 5.96 |
| — | +116.1% | +115.9% | +92.8% | +171.4% | +5.8% | +16.3% | +47.1% | -18.1% | +20.6% | +11.1% | +21.7% | +20.5% | +1.6% | -6.0% | -13.1% | -18.0% | -50.0% | +5.5% | +12.4% | +98.0% | |
| Quick Ratio | 13.09 | 13.00 | 14.57 | 16.99 | 13.09 | 6.02 | 6.75 | 8.81 | 4.82 | 5.69 | 5.81 | 5.99 | 5.89 | 4.72 | 5.22 | 4.92 | 4.89 | 4.64 | 5.56 | 5.66 | 5.96 |
| — | +116.1% | +115.9% | +92.8% | +171.4% | +5.8% | +16.3% | +47.1% | -18.1% | +20.6% | +11.1% | +21.7% | +20.5% | +1.6% | -6.0% | -13.1% | -18.0% | -50.0% | +5.5% | +12.4% | +98.0% | |
| Interest Coverage | -0.83 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 33 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BEAM stock.
Beam Therapeutics Inc.'s current P/E is -25.8x. The average P/E over the last 1 quarters is 3.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Beam Therapeutics Inc.'s current operating margin is -274.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Beam Therapeutics Inc.'s business trajectory between earnings reports.